GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses - PubMed

10 hours ago

GLP-1 receptor agonists are primarily used for type 2 diabetes and obesity, but their effects on noncardiometabolic outcomes are unclear.
An umbrella review analyzed 60 meta-analyses covering 116 adverse health outcomes from 1751 RCTs with over 3.5 million participants.
Strongest evidence links GLP-1 RAs to increased gastrointestinal adverse events like nausea, vomiting, and diarrhea, with moderate to high certainty.
Possible protective associations were observed for serious infections and respiratory diseases, requiring further confirmation.
Other outcomes such as gastrointestinal disease and biliary events did not meet high credibility thresholds and remain exploratory.
Most noncardiometabolic outcomes associated with GLP-1 RAs have lower certainty evidence, highlighting the need for more research.

Hasty Briefsbeta